Connection

Contact Us
If you have any questions or feedback please contact us.

Search Results to Daniel W Bowles

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Bowles, Daniel

One or more keywords matched the following items that are connected to Bowles, Daniel

Item Type	Name
Academic Article	Mitoxantrone-associated acute myelogenous leukemia in a patient with high-risk adenocarcinoma of the prostate: a case report and brief review.
Academic Article	Vismodegib in basal cell carcinoma.
Academic Article	Axitinib, a new therapeutic option in renal cell carcinoma.
Academic Article	Tivozanib: practical implications for renal cell carcinoma and other solid tumors.
Academic Article	New phosphatidylinositol 3-kinase inhibitors for cancer.
Academic Article	Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).
Academic Article	Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
Concept	Antineoplastic Agents
Academic Article	A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.
Academic Article	Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer.
Academic Article	Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
Academic Article	Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.
Academic Article	Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.
Academic Article	A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma.
Academic Article	Successes and Failures of Combined Modality Therapies in Head and Neck Cancer.
Academic Article	Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity.
Academic Article	Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin.
Academic Article	Cabozantinib use in renal cell carcinoma.
Academic Article	Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.
Academic Article	Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population.
Academic Article	Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
Academic Article	The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Academic Article	Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients.
Academic Article	Update on multikinase inhibitor therapy for differentiated thyroid cancer.
Academic Article	New therapies for anaplastic thyroid cancer.
Concept	Antineoplastic Agents, Immunological
Academic Article	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Academic Article	Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Academic Article	ROS1 Targeted Therapies: Current Status.
Academic Article	Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI).
Academic Article	Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
Academic Article	A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
Academic Article	Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.

Search Criteria

Antineoplastic Agents